article · ACS Omega
Type II diabetes involves high blood sugar, insulin resistance, and impaired pancreatic function. An investigation into the therapeutic effects of zinc oxide nanoparticles and a synthesized pyrazolopyrimidine compound evaluated their impacts individually and in combination using diabetic rat models over thirty days. Untreated diabetic rats showed raised levels of blood glucose, liver enzymes, harmful blood lipids, malondialdehyde, and hepatic PGC-1alpha gene expression, alongside reduced insulin, beneficial cholesterol, superoxide dismutase, and CPT1A gene expression. Daily oral administration of zinc oxide nanoparticles, pyrazolopyrimidine, or both treatments together counteracted these adverse biochemical shifts. Overall, the treatments lowered blood sugar, supported antioxidant defences, improved lipid profiles, and normalised both liver enzymes and the expression of key metabolic genes in the liver.
Type II diabetes affects metabolic health throughout the body, frequently causing liver strain, lipid imbalances, and oxidative stress alongside poor blood sugar control. Studying therapeutic agents that simultaneously target high glucose, organ health, and antioxidant defences helps researchers better understand how combined treatments might counteract the broad systemic complications linked to metabolic disease.
This work represents early-stage preclinical research conducted in animal models. The findings may interest pharmaceutical researchers and drug discovery teams exploring novel therapeutics or combination regimens for metabolic conditions like type II diabetes. Because the study is limited to rodent trials, extensive toxicology, pharmacological optimisation, and human clinical trials would be necessary before any healthcare or market application is possible.
AI-generated from the published abstract. Always read the original work before citing.
Diabetes mellitus (DM) is a category of metabolic illness characterized by high blood sugar levels and insufficient pancreatic insulin production or activity within the body. The most common type of diabetes is type II diabetes, which is a metabolic condition characterized by insulin resistance and pancreatic islet β-cell failure, resulting in hyperglycemia. The goal of this study was to examine the anti-diabetic implications of zinc oxide nanoparticles (ZnO NPs) and/or pyrazolopyrimidine in type II diabetic rats. Rats with a weight of 150 ± 20 g were used. Animals were divided into five groups as follows: group 1: control, group 2: type II diabetic rats, group 3: diabetic rats received ZnO NPs (10 mg/kg/orally/day), group 4: diabetic rats received pyrazolopyrimidine (5 mg/kg/orally/day), and group 5: diabetic rats received ZnO NPs (10 mg/kg/orally/day) + pyrazolopyrimidine (5 mg/kg/orally/day), respectively, for 30 days. The results indicated that serum glucose, total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein-cholesterol (LDL-c), very low-density lipoprotein-cholesterol (VLDL-c), malondialdehyde, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha PGC-1α mRNA expressions were increased in the diabetic group versus the control group, while serum insulin, high-density lipoprotein-cholesterol (HDL-c), superoxide dismutase (SOD), and carnitine palmitoyltransferase 1A (CPT1A) mRNA expression levels were decreased. These parameters were reserved in the treated groups (ZnO NPs, pyrazolopyrimidine, and ZnO NPs + pyrazolopyrimidine). This study proved that ZnO NPs and pyrazolopyrimidine had an ameliorative effect on blood glucose levels, antioxidant status, lipid profile, liver function enzymes, and mRNA expression of hepatic genes.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1021/acsomega.2c05638
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
